Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.
MER Indicator |
MER description |
Target Fiscal Year |
Target |
HTS_TST |
25-29, Female, Negative |
2019 |
2,258 |
HTS_TST |
25-29, Female, Negative |
2019 |
151 |
HTS_TST |
25-29, Male, Negative |
2019 |
959 |
HTS_TST |
25-29, Male, Negative |
2019 |
1,829 |
HTS_TST |
25-29, Male, Negative |
2019 |
101 |
HTS_TST |
30-34, Female, Negative |
2019 |
3,215 |
HTS_TST |
30-34, Female, Negative |
2019 |
201 |
HTS_TST |
30-34, Male, Negative |
2019 |
959 |
HTS_TST |
30-34, Male, Negative |
2019 |
3,087 |
HTS_TST |
30-34, Male, Negative |
2019 |
168 |
HTS_TST |
35-39, Female, Negative |
2019 |
3,180 |
HTS_TST |
35-39, Female, Negative |
2019 |
177 |
HTS_TST |
35-39, Male, Negative |
2019 |
4,134 |
HTS_TST |
35-39, Male, Negative |
2019 |
196 |
HTS_TST |
40-49, Female, Negative |
2019 |
4,554 |
HTS_TST |
40-49, Female, Negative |
2019 |
294 |
HTS_TST |
40-49, Male, Negative |
2019 |
1 |
HTS_TST |
40-49, Male, Negative |
2019 |
7,388 |
HTS_TST |
40-49, Male, Negative |
2019 |
441 |
HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2019 |
3,248 |
HTS_TST |
Number of individuals who received T&C services for HIV and received their test results during the past 12 months |
2019 |
52,797 |
HTS_TST |
Service Delivery Point (Facility) Other PITC: 1-9, Negative |
2019 |
18 |
HTS_TST |
Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative |
2019 |
4 |
HTS_TST |
Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative |
2019 |
4 |
HTS_TST |
Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative |
2019 |
1,788 |
HTS_TST |
Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative |
2019 |
809 |
HTS_TST |
Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative |
2019 |
6,286 |
HTS_TST |
Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative |
2019 |
1,211 |
HTS_TST |
Service Delivery Point (Facility) Other PITC: 50+, Female, Negative |
2019 |
1,461 |
HTS_TST |
Service Delivery Point (Facility) Other PITC: 50+, Male, Negative |
2019 |
2,471 |
HTS_TST |
Service Delivery Point (Facility) TB: 1-9, Negative |
2019 |
170 |
HTS_TST |
Service Delivery Point (Facility) TB: 10-14, Female, Negative |
2019 |
36 |
HTS_TST |
Service Delivery Point (Facility) TB: 10-14, Male, Negative |
2019 |
36 |
HTS_TST |
Service Delivery Point (Facility) TB: 15-19, Female, Negative |
2019 |
106 |
HTS_TST |
Service Delivery Point (Facility) TB: 15-19, Male, Negative |
2019 |
68 |
HTS_TST |
Service Delivery Point (Facility) TB: 20-24, Female, Negative |
2019 |
1 |
HTS_TST |
Service Delivery Point (Facility) TB: 20-24, Female, Negative |
2019 |
337 |
HTS_TST |
Service Delivery Point (Facility) TB: 20-24, Male, Negative |
2019 |
33 |
HTS_TST |
Service Delivery Point (Facility) TB: 50+, Female, Negative |
2019 |
49 |
HTS_TST |
Service Delivery Point (Facility) TB: 50+, Male, Negative |
2019 |
80 |
HTS_TST |
Service Delivery Point (Facility) VMMC: 15-19, Negative |
2019 |
318 |
HTS_TST |
Service Delivery Point (Facility) VMMC: 20-24, Negative |
2019 |
956 |
HTS_TST_POS |
25-29, Female, Positive |
2019 |
210 |
HTS_TST_POS |
25-29, Female, Positive |
2019 |
129 |
HTS_TST_POS |
25-29, Male, Positive |
2019 |
15 |
HTS_TST_POS |
25-29, Male, Positive |
2019 |
189 |
HTS_TST_POS |
25-29, Male, Positive |
2019 |
82 |
HTS_TST_POS |
30-34, Female, Positive |
2019 |
312 |
HTS_TST_POS |
30-34, Female, Positive |
2019 |
164 |
HTS_TST_POS |
30-34, Male, Positive |
2019 |
15 |
HTS_TST_POS |
30-34, Male, Positive |
2019 |
289 |
HTS_TST_POS |
30-34, Male, Positive |
2019 |
139 |
HTS_TST_POS |
35-39, Female, Positive |
2019 |
309 |
HTS_TST_POS |
35-39, Female, Positive |
2019 |
146 |
HTS_TST_POS |
35-39, Male, Positive |
2019 |
432 |
HTS_TST_POS |
35-39, Male, Positive |
2019 |
174 |
HTS_TST_POS |
40-49, Female, Positive |
2019 |
449 |
HTS_TST_POS |
40-49, Female, Positive |
2019 |
249 |
HTS_TST_POS |
40-49, Male, Positive |
2019 |
812 |
HTS_TST_POS |
40-49, Male, Positive |
2019 |
337 |
HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 1-9, Positive |
2019 |
2 |
HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive |
2019 |
1 |
HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive |
2019 |
1 |
HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive |
2019 |
186 |
HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive |
2019 |
82 |
HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive |
2019 |
669 |
HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive |
2019 |
130 |
HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 50+, Female, Positive |
2019 |
124 |
HTS_TST_POS |
Service Delivery Point (Facility) Other PITC: 50+, Male, Positive |
2019 |
231 |
HTS_TST_POS |
Service Delivery Point (Facility) TB: 1-9, Positive |
2019 |
64 |
HTS_TST_POS |
Service Delivery Point (Facility) TB: 10-14, Female, Positive |
2019 |
34 |
HTS_TST_POS |
Service Delivery Point (Facility) TB: 10-14, Male, Positive |
2019 |
26 |
HTS_TST_POS |
Service Delivery Point (Facility) TB: 15-19, Female, Positive |
2019 |
76 |
HTS_TST_POS |
Service Delivery Point (Facility) TB: 15-19, Male, Positive |
2019 |
32 |
HTS_TST_POS |
Service Delivery Point (Facility) TB: 20-24, Female, Positive |
2019 |
237 |
HTS_TST_POS |
Service Delivery Point (Facility) TB: 20-24, Male, Positive |
2019 |
24 |
HTS_TST_POS |
Service Delivery Point (Facility) TB: 50+, Female, Positive |
2019 |
45 |
HTS_TST_POS |
Service Delivery Point (Facility) TB: 50+, Male, Positive |
2019 |
70 |
HTS_TST_POS |
Service Delivery Point (Facility) VMMC: 15-19, Positive |
2019 |
3 |
HTS_TST_POS |
Service Delivery Point (Facility) VMMC: 20-24, Positive |
2019 |
20 |
HTS_TST_POS |
Service Delivery Point (Facility) VMMC: 50+, Positive |
2019 |
1 |
KP_PREV |
By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2019 |
32,539 |
KP_PREV |
By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) |
2019 |
37,005 |
KP_PREV |
Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required |
2019 |
32,539 |
KP_PREV |
Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required |
2019 |
37,005 |
TB_ART |
Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) |
2019 |
129 |
TB_ART |
Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) |
2019 |
3,236 |
TB_ART |
The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period |
2019 |
3,365 |
TB_STAT |
Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2019 |
249 |
TB_STAT |
Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) |
2019 |
5,901 |
TB_STAT |
Number of registered new and relapsed TB cases with documented HIV status, during the reporting period |
2019 |
6,142 |
TB_STAT |
Total number of registered new and relapsed TB cases, during the reporting period |
2019 |
6,284 |
TB_STAT_den |
Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) |
2019 |
195 |
TB_STAT_den |
Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) |
2019 |
6,012 |
TX_CURR |
25-29, Female, Positive |
2019 |
2 |
TX_CURR |
25-29, Female, Positive |
2019 |
428 |
TX_CURR |
25-29, Male, Positive |
2019 |
58 |
TX_CURR |
25-29, Male, Positive |
2019 |
10,293 |
TX_CURR |
30-34, Female, Positive |
2019 |
2 |
TX_CURR |
30-34, Female, Positive |
2019 |
517 |
TX_CURR |
30-34, Male, Positive |
2019 |
63 |
TX_CURR |
30-34, Male, Positive |
2019 |
11,932 |
TX_CURR |
35-39, Female, Positive |
2019 |
197 |
TX_CURR |
35-39, Male, Positive |
2019 |
28 |
TX_CURR |
35-39, Male, Positive |
2019 |
5,105 |
TX_CURR |
40-49, Female, Positive |
2019 |
2 |
TX_CURR |
40-49, Female, Positive |
2019 |
278 |
TX_CURR |
40-49, Male, Positive |
2019 |
36 |
TX_CURR |
40-49, Male, Positive |
2019 |
6,830 |
TX_CURR |
Age/Sex: 15-19 Female |
2019 |
24 |
TX_CURR |
Age/Sex: 15-19 Male |
2019 |
3 |
TX_CURR |
Age/Sex: 15-19 Male |
2019 |
705 |
TX_CURR |
Age/Sex: 20-24 Female |
2019 |
2 |
TX_CURR |
Age/Sex: 20-24 Female |
2019 |
299 |
TX_CURR |
Age/Sex: 20-24 Male |
2019 |
24 |
TX_CURR |
Age/Sex: 20-24 Male |
2019 |
4,412 |
TX_CURR |
Age/Sex: 50+ Female |
2019 |
2 |
TX_CURR |
Age/Sex: 50+ Female |
2019 |
428 |
TX_CURR |
Age/Sex: 50+ Male |
2019 |
11 |
TX_CURR |
Age/Sex: 50+ Male |
2019 |
2,114 |
TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2019 |
233 |
TX_CURR |
Number of adults and children receiving antiretroviral therapy (ART) |
2019 |
43,562 |
TX_CURR |
Sum of age/sex disaggregates |
2019 |
3 |
TX_CURR |
Sum of Age/Sex disaggregations |
2019 |
729 |
TX_NEW |
25-29, Female, Positive |
2019 |
447 |
TX_NEW |
25-29, Male, Positive |
2019 |
4,350 |
TX_NEW |
30-34, Female, Positive |
2019 |
54 |
TX_NEW |
30-34, Male, Positive |
2019 |
4,350 |
TX_NEW |
35-39, Male, Positive |
2019 |
8 |
TX_NEW |
By Age/Sex: 15-19 Female |
2019 |
261 |
TX_NEW |
By Age/Sex: 15-19 Male |
2019 |
56 |
TX_NEW |
By Age/Sex: 20-24 Female |
2019 |
197 |
TX_NEW |
By Age/Sex: 20-24 Male |
2019 |
835 |
TX_NEW |
By Age/Sex: 50+ Female |
2019 |
3 |
TX_NEW |
By Age/Sex: 50+ Male |
2019 |
56 |
TX_NEW |
Number of adults and children newly enrolled on antiretroviral therapy (ART) |
2019 |
10,632 |
TX_NEW |
People in prisons and other enclosed settings |
2019 |
10,632 |
TX_NEW |
Sum of Age/Sex disaggregates |
2019 |
1,408 |
TX_TB |
Number of ART patients who were screened for TB at least once during the reporting period |
2019 |
3,365 |
TX_TB_den |
Denominator: By Aggregated Age/Sex: 15+, Female |
2019 |
129 |
TX_TB_den |
Denominator: By Aggregated Age/Sex: 15+, Male |
2019 |
3,237 |
VMMC_CIRC |
30-34, Male |
2019 |
647 |
VMMC_CIRC |
By Age: 15-19 |
2019 |
263 |
VMMC_CIRC |
By Age: 20-24 |
2019 |
1,177 |
VMMC_CIRC |
By Age: 25-29 |
2019 |
1,179 |
VMMC_CIRC |
By circumcision technique: Surgical VMMC |
2019 |
3,265 |
VMMC_CIRC |
Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period |
2019 |
3,265 |
VMMC_CIRC |
Sum of age disaggregates (FY15-Current) |
2019 |
2,619 |
VMMC_CIRC |
Sum of age disaggregates (Prior to FY15) |
2019 |
1,440 |